- Poster presentation
- Open Access
Hydrogen sulfide for organ protection
Critical Care volume 12, Article number: P389 (2008)
Pharmacological and biological actions of the gaseous biological mediator hydrogen sulfide include vasodilatation, cytoprotection, inhibition of mitochondrial respiration as well as induction of a state akin to suspended animation.
Rodent models of ischemia and reperfusion of the heart and the liver were employed, as well as a model of acute respiratory distress syndrome. A dog model of cardiopulmonary bypass, an ovine model of acute respiratory distress syndrome induced by burn and smoke inhalation as well as a pig model of myocardial infarction were used. Hydrogen sulfide was administered to the animals in a stable, iso-osmolar, pH-neutral intravenous injectable formulation (IK-1001; sodium sulfide for injection).
In a rat study of myocardial infarction, a significant protection was seen in terms of reduction of myocardial infarct size. In a mouse model of myocardial infarction, IK-1001 reduced infarct size, reduced neutrophil infiltration, attenuated the inflammatory response, and improved contractility. The cardiac protection was also confirmed in large animal models: in a porcine model of myocardial ischemia, reduction of infarct size and improvement of cardiac contractility was seen. Improvement of cardiac contractility and preservation of endothelium-dependent relaxant responses were seen in a dog cardiopulmonary bypass model. Protection was also seen in a mouse model of liver ischemia-reperfusion injury. The protective effect of IK-1001 was also demonstrated in a mouse and in a sheep model of acute respiratory distress syndrome, evidenced by improved survival rate, and downregulation of the inflammatory response.
The current presentation overviews some of the recent data demonstrating the organ protective effects of hydrogen sulfide. The mechanism of protection probably involves multiple effects including metabolic effects, antioxidant mechanisms, activation of KATP channels, as well as inhibition of inflammatory cell activation.
Blackstone E, et al.: Science. 2005, 308: 518. 10.1126/science.1108581
Szabó C: Nat Rev Drug Discov. 2007, 6: 917-935. 10.1038/nrd2425
Elrod JW, et al.: Proc Natl Acad Sci USA. 2007, 104: 15560-15565. 10.1073/pnas.0705891104
Blackstone E, et al.: Shock. 2007, 27: 370-372. 10.1097/SHK.0b013e31802e27a0
About this article
Cite this article
Szabo, C. Hydrogen sulfide for organ protection. Crit Care 12, P389 (2008). https://doi.org/10.1186/cc6610
- Infarct Size
- Cardiopulmonary Bypass
- Acute Respiratory Distress Syndrome
- Hydrogen Sulfide
- KATP Channel